MTI Aims To Rebound From Onyx Trial Delays, Focuses European Business
This article was originally published in The Gray Sheet
Executive Summary
Micro Therapeutics, Inc.'s pivotal study of its Onyx liquid embolic system for the treatment of brain aneurysms will remain on target for completion by the third quarter of 2002, with 138 patients on board as predicted, the firm says